Lantus up last week, but new scrips fall

In the wake of new safety concerns about the drug, total U.S. prescription volume for the Sanofi-Aventis diabetes drug Lantus inched up 2 percent last week versus the week before, but new prescriptions were down 3.8 percent, according to a drug-data provider. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.